Enliven Therapeutics begins patient dosing in oncology drug trial
Enliven Therapeutics Inc. (Nasdaq: ELVN), a clinical-stage precision oncology company, began dosing patients in clinical trials for two of its drug candidates during the second quarter of 2024.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
